trial
as of 2026-07-01A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients
NCTId NCT01730768
at a glance
Phase 2 · Completed
Enrollment 147 (actual)
Sponsored by Novartis Pharmaceuticals
Primary completion 2013-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
147 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2012-09
Primary completion
2013-12
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Drugs
Indications
Sponsors
Novartis PharmaceuticalsLead Sponsor
Sites
13 total
Garden Grove, United StatesGlendale, United StatesNational City, United StatesOakland, United StatesPico Rivera, United StatesSan Diego, United StatesMiramar, United StatesAtlanta, United StatesMarlton, United StatesStaten Island, United StatesStaten Island, United StatesPhiladelphia, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
147
Phase
PHASE2
Primary Completion Date
2013-12
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication